Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.

Platinum-based chemotherapy is the mainstay of front-line therapy of sufferers affected by pluri-metastatic intermediate/excessive grade NeuroEndocrine Neoplasms (NENs). Nevertheless, there aren’t any commonplace second-line remedies at illness development.

Earlier scientific experiences have evidenced that temozolomide (TMZ), an oral analog of dacarbazine, is lively in opposition to NENs at commonplace doses of 150 to 200 mg/mq per day on days 1 to five of a 28-day cycle, even when a major treatment-related toxicity is reported.

METHODS

Metastatic NENs sufferers had been handled on the ENETS (European NeuroEndocrine Tumor Society) heart of excellence of Naples (Italy), from 2014 to 2017 with a second-line various metronomic schedule of TMZ, 75 mg/m2per os “one week on/one week off”. Toxicity was graded with NCI-CTC standards v4.0; goal responses with RECIST v1.1 and efficiency standing (PS) in accordance with ECOG.

Twenty-six consecutive sufferers had been handled. Median age was 65.5 years. The predominant main organs had been pancreas and lung. Grading was G2 in 11 sufferers, G3 in 15. Greater than half of sufferers had a PS 2 (15 vs. 11 with PS 1). The median time-on-temozolomide remedy was 12.2 months (95% CI: 11.4-19.6). No G3/G4 toxicities had been registered.

Full response was obtained in 1 affected person, partial response in 4, steady illness in 19 (illness management price: 92.3%), and progressive illness in 2. The median total survival from TMZ begin was 28.Three months. PS improved in 73% of sufferers.Metronomic TMZ is an acceptable therapy for G2 and G3 NENs significantly in PS 2 sufferers. Potential and bigger trials are wanted to verify these outcomes.

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.
Security and Exercise of Metronomic Temozolomide in Second-Line Remedy of Superior Neuroendocrine Neoplasms.

Would ivermectin for malaria management be useful in onchocerciasis-endemic areas?

There may be accumulating proof supporting using ivermectin as a malaria management software. Latest findings from the repeat ivermectin mass drug administrations for management of malaria trial demonstrated a diminished incidence of malaria in villages which obtained repeated ivermectin mass drug administration (MDA; six doses) in comparison with those that had just one spherical of ivermectin.

EEF1A2

MBS9125428-01mL 0.1mL
EUR 345

EEF1A2

MBS9125428-02mL 0.2mL
EUR 545

EEF1A2

MBS9125428-5x02mL 5x0.2mL
EUR 2265

EEF1A2

MBS8563645-01mLAF405L 0.1mL(AF405L)
EUR 565

EEF1A2

MBS8563645-01mLAF405S 0.1mL(AF405S)
EUR 565

EEF1A2

MBS8563645-01mLAF610 0.1mL(AF610)
EUR 565

EEF1A2

MBS8563645-01mLAF635 0.1mL(AF635)
EUR 565

EEF1A2

MBS8563645-02mL 0.2mL
EUR 345

EEF1A2 siRNA

20-abx914976
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

EEF1A2 siRNA

20-abx914977
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

EEF1A2 siRNA

20-abx901643
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

EEF1A2 Peptide

43-205P 0.1 mg
EUR 405.6

EEF1A2 Antibody

45965-100ul 100ul
EUR 302.4

EEF1A2 Antibody

45965-50ul 50ul
EUR 224.4

EEF1A2 Antibody

DF9493 200ul
EUR 420

EEF1A2 Antibody

DF9493-100ul 100ul
EUR 280

EEF1A2 Antibody

DF9493-200ul 200ul
EUR 350

EEF1A2 antibody

E39-10409 100ug/100ul
EUR 225
Description: Available in various conjugation types.

eEF1A2 Antibody

E92473 100ul
EUR 255
Description: Available in various conjugation types.

EEF1A2 Antibody

E311602 200ul
EUR 275
Description: Available in various conjugation types.

EEF1A2 Antibody

E19-9493-1 50ug/50ul
EUR 145
Description: Available in various conjugation types.

EEF1A2 Antibody

E19-9493-2 100ug/100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 antibody

70R-17001 50 ul
EUR 289
Description: Rabbit polyclonal EEF1A2 antibody

EEF1A2 antibody

70R-3046 50 ug
EUR 467
Description: Rabbit polyclonal EEF1A2 antibody raised against the middle region of EEF1A2

EEF1A2 Antibody

AF6618 100ul
EUR 420

EEF1A2 Antibody

AF6618-100ul 100ul
EUR 280

EEF1A2 Antibody

AF6618-200ul 200ul
EUR 350

EEF1A2 Antibody

1-CSB-PA007412ESR1HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against EEF1A2. Recognizes EEF1A2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

EEF1A2 Antibody

1-CSB-PA007412ESR2HU
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against EEF1A2. Recognizes EEF1A2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200

EEF1A2 Antibody

1-CSB-PA007412GA01HU
  • Ask for price
  • Ask for price
  • 150ul
  • 50ul
Description: A polyclonal antibody against EEF1A2. Recognizes EEF1A2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC

EEF1A2 Antibody

ABD9493 100ug
EUR 325

EEF1A2 Antibody

GWB-MR059E 50ug Ask for price

EEF1A2 Antibody

R34872-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Eukaryotic translation elongation factor 1 alpha 2, EEF1AL, EF-1-alpha-2; EEF1A2

EEF1A2 Antibody

MBS7044252-005mL 0.05mL
EUR 190

EEF1A2 Antibody

MBS7044252-01mL 0.1mL
EUR 270

EEF1A2 Antibody

MBS7044252-5x01mL 5x0.1mL
EUR 1205

EEF1A2 Antibody

MBS7044431-005mL 0.05mL
EUR 190

EEF1A2 Antibody

MBS7044431-01mL 0.1mL
EUR 270

EEF1A2 Antibody

MBS7044431-5x01mL 5x0.1mL
EUR 1205

eEF1A2 Antibody

MBS8504964-01mL 0.1mL
EUR 325

eEF1A2 Antibody

MBS8504964-01mLAF405L 0.1mL(AF405L)
EUR 565

eEF1A2 Antibody

MBS8504964-01mLAF405S 0.1mL(AF405S)
EUR 565

eEF1A2 Antibody

MBS8504964-01mLAF610 0.1mL(AF610)
EUR 565

eEF1A2 Antibody

MBS8504964-01mLAF635 0.1mL(AF635)
EUR 565

EEF1A2 Antibody

MBS8518504-005mg 0.05mg
EUR 235

EEF1A2 Antibody

MBS8518504-01mg 0.1mg
EUR 305

EEF1A2 Antibody

MBS8518504-01mLAF405M 0.1mL(AF405M)
EUR 465

EEF1A2 Antibody

MBS8518504-01mLAF546 0.1mL(AF546)
EUR 465

EEF1A2 Antibody

MBS8518504-01mLAF750 0.1mL(AF750)
EUR 465

EEF1A2 Antibody

MBS9609810-01mL 0.1mL
EUR 260

EEF1A2 Antibody

MBS9609810-02mL 0.2mL
EUR 305

EEF1A2 Antibody

MBS9609810-5x02mL 5x0.2mL
EUR 1220

EEF1A2 Antibody

MBS9613639-01mL 0.1mL
EUR 260

EEF1A2 Antibody

MBS9613639-02mL 0.2mL
EUR 305

EEF1A2 Antibody

MBS9613639-5x02mL 5x0.2mL
EUR 1220

EEF1A1 / EEF1A2 / EEF1A1P5 Antibody

20-abx327705
  • Ask for price
  • Ask for price
  • 100 ug
  • 50 ug

EEF1A1/EEF1A2/EEF1A1P5 Antibody

1-CSB-PA005918
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EEF1A1/EEF1A2/EEF1A1P5. Recognizes EEF1A1/EEF1A2/EEF1A1P5 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

EEF1A1 / EEF1A2 / EEF1A1P5 Antibody

abx327705-100g 100 µg
EUR 250

EEF1A1 / EEF1A2 / EEF1A1P5 Antibody

abx327705-50g 50 µg
EUR 187.5

EEF1A1/EEF1A2/EEF1A1P5 Antibody

MBS7117700-005mg 0.05mg
EUR 150

EEF1A1/EEF1A2/EEF1A1P5 Antibody

MBS7117700-01mg 0.1mg
EUR 190

EEF1A1/EEF1A2/EEF1A1P5 Antibody

MBS7117700-5x01mg 5x0.1mg
EUR 845

EEF1A2 siRNA (Rat)

MBS827163-15nmol 15nmol
EUR 405

EEF1A2 siRNA (Rat)

MBS827163-30nmol 30nmol
EUR 565

EEF1A2 siRNA (Rat)

MBS827163-5x30nmol 5x30nmol
EUR 2450

EEF1A2 Rabbit pAb

A7327-100ul 100 ul
EUR 369.6

EEF1A2 Rabbit pAb

A7327-200ul 200 ul
EUR 550.8

EEF1A2 Rabbit pAb

A7327-20ul 20 ul
EUR 219.6

EEF1A2 Rabbit pAb

A7327-50ul 50 ul
EUR 267.6

EEF1A2 Rabbit pAb

E2502473 100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 Rabbit pAb

E2507327 100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 Rabbit pAb

A2473-100ul 100 ul
EUR 369.6

EEF1A2 Rabbit pAb

A2473-200ul 200 ul
EUR 550.8

EEF1A2 Rabbit pAb

A2473-20ul 20 ul
EUR 219.6

EEF1A2 Rabbit pAb

A2473-50ul 50 ul
EUR 267.6

EEF1A2 Rabbit pAb

MBS8546738-01mL 0.1mL
EUR 305

EEF1A2 Rabbit pAb

MBS8546738-01mLAF405L 0.1mL(AF405L)
EUR 565

EEF1A2 Rabbit pAb

MBS8546738-01mLAF405S 0.1mL(AF405S)
EUR 565

EEF1A2 Rabbit pAb

MBS8546738-01mLAF610 0.1mL(AF610)
EUR 565

EEF1A2 Rabbit pAb

MBS8546738-01mLAF635 0.1mL(AF635)
EUR 565

EEF1A2 Rabbit pAb

MBS8544928-01mL 0.1mL
EUR 305

EEF1A2 Rabbit pAb

MBS8544928-01mLAF405L 0.1mL(AF405L)
EUR 565

EEF1A2 Rabbit pAb

MBS8544928-01mLAF405S 0.1mL(AF405S)
EUR 565

EEF1A2 Rabbit pAb

MBS8544928-01mLAF610 0.1mL(AF610)
EUR 565

EEF1A2 Rabbit pAb

MBS8544928-01mLAF635 0.1mL(AF635)
EUR 565

EEF1A2 Rabbit mAb

MBS4753252-01mL 0.1mL
EUR 450

EEF1A2 Rabbit mAb

MBS4753252-5x01mL 5x0.1mL
EUR 1540

EEF1A2 Rabbit pAb

A2473 1000μL
EUR 88.56

EEF1A2 Rabbit pAb

A7327 1000μL
EUR 70.85

EEF1A2 siRNA (Human)

MBS8202962-15nmol 15nmol
EUR 405

EEF1A2 siRNA (Human)

MBS8202962-30nmol 30nmol
EUR 565

EEF1A2 siRNA (Human)

MBS8202962-5x30nmol 5x30nmol
EUR 2450

EEF1A2 siRNA (Mouse)

MBS8206897-15nmol 15nmol
EUR 405

EEF1A2 siRNA (Mouse)

MBS8206897-30nmol 30nmol
EUR 565

EEF1A2 siRNA (Mouse)

MBS8206897-5x30nmol 5x30nmol
EUR 2450

Human EEF1a2 Protein

20-abx650911
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

anti- EEF1A2 antibody

FNab02642 100µg
EUR 606.3
Description: Antibody raised against EEF1A2

Human EEF1a2 Protein

abx650911-5mg 5 mg
EUR 337.5

EEF1A2 Blocking Peptide

33R-9588 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of EEF1A2 antibody, catalog no. 70R-3046

EEF1A2 Blocking Peptide

DF9493-BP 1mg
EUR 234

EEF1A2 Blocking Peptide

MBS9617720-1mg 1mg
EUR 380

EEF1A2 Blocking Peptide

MBS9617720-5x1mg 5x1mg
EUR 1650

EEF1A2 Blocking Peptide

MBS9628514-1mg 1mg
EUR 380

EEF1A2 Blocking Peptide

MBS9628514-5x1mg 5x1mg
EUR 1650

Recombinant Human EEF1A2

P0565 100ug
EUR 626.83
Description: Recombinant Human protein for EEF1A2

Recombinant Human EEF1A2

MBS7608636-005mg 0.05mg
EUR 345

Recombinant Human EEF1A2

MBS7608636-02mg 0.2mg
EUR 635

Recombinant Human EEF1A2

MBS7608636-1mg 1mg
EUR 1800

Recombinant Human EEF1A2

MBS7608636-5x1mg 5x1mg
EUR 6955

EEF1A2 Immunizing Peptide

MBS427810-01mg 0.1mg
EUR 225

EEF1A2 Polyclonal Antibody

E97327 100ul
EUR 225
Description: Available in various conjugation types.

EEF1A2 Conjugated Antibody

C45965 100ul
EUR 476.4

EEF1A2 Polyclonal Antibody

MBS126428-002mL 0.02mL
EUR 200

EEF1A2 Polyclonal Antibody

MBS126428-005mL 0.05mL
EUR 255

EEF1A2 Polyclonal Antibody

MBS126428-01mL 0.1mL
EUR 345

EEF1A2 Polyclonal Antibody

MBS126428-02mL 0.2mL
EUR 545

EEF1A2 Polyclonal Antibody

MBS126428-5x02mL 5x0.2mL
EUR 2265

EEF1A2 Polyclonal Antibody

E-AB-61648-120uL 120uL
EUR 320
Description: Unconjugated

EEF1A2 Polyclonal Antibody

E-AB-61648-200uL 200uL
EUR 530
Description: Unconjugated

EEF1A2 Polyclonal Antibody

E-AB-61648-60uL 60uL
EUR 200
Description: Unconjugated

EEF1A2 Polyclonal Antibody

E-AB-61648-each each Ask for price
Description: Unconjugated

EEF1A2 Polyclonal Antibody

MBS8573337-01mL 0.1mL
EUR 305

EEF1A2 Polyclonal Antibody

MBS8573337-01mLAF405L 0.1mL(AF405L)
EUR 565

EEF1A2 Polyclonal Antibody

MBS8573337-01mLAF405S 0.1mL(AF405S)
EUR 565

EEF1A2 Polyclonal Antibody

MBS8573337-01mLAF610 0.1mL(AF610)
EUR 565

EEF1A2 Polyclonal Antibody

MBS8573337-01mLAF635 0.1mL(AF635)
EUR 565

EEF1A2 Polyclonal Antibody

MBS2538211-006mL 0.06mL
EUR 190

EEF1A2 Polyclonal Antibody

MBS2538211-012mL 0.12mL
EUR 265

EEF1A2 Polyclonal Antibody

MBS2538211-02mL 0.2mL
EUR 415

EEF1A2 Polyclonal Antibody

MBS2538211-5x02mL 5x0.2mL
EUR 1835

Recombinant EEF1A2 protein

MBS389269-002mg 0.02mg
EUR 610

Recombinant EEF1A2 protein

MBS389269-1mg 1mg
EUR 3345

Recombinant EEF1A2 protein

MBS389269-5x1mg 5x1mg
EUR 14870

EEF1A2 Conjugated Antibody

MBS9453917-01mLAF350 0.1mL(AF350)
EUR 480

EEF1A2 Conjugated Antibody

MBS9453917-01mLAF405 0.1mL(AF405)
EUR 480

EEF1A2 Conjugated Antibody

MBS9453917-01mLAF488 0.1mL(AF488)
EUR 480

EEF1A2 Conjugated Antibody

MBS9453917-01mLAF555 0.1mL(AF555)
EUR 480

EEF1A2 Conjugated Antibody

MBS9453917-01mLBiotin 0.1mL(Biotin)
EUR 480

EEF1A2 Polyclonal Antibody

RD84423A-120uL 120μL
EUR 360
Description: This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer.

EEF1A2 Polyclonal Antibody

RD84423A-200uL 200μL
EUR 630
Description: This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer.

EEF1A2 Polyclonal Antibody

RD84423A-60uL 60μL
EUR 204
Description: This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer.

EEF1A2 Polyclonal Antibody

RD82636A-120uL 120μL
EUR 360
Description: This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer.

EEF1A2 Polyclonal Antibody

RD82636A-200uL 200μL
EUR 630
Description: This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer.

EEF1A2 Polyclonal Antibody

RD82636A-60uL 60μL
EUR 204
Description: This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. This isoform (alpha 2) is expressed in brain, heart and skeletal muscle, and the other isoform (alpha 1) is expressed in brain, placenta, lung, liver, kidney, and pancreas. This gene may be critical in the development of ovarian cancer.

Human EEF1A2 ELISA KIT

EF009296 96tests
EUR 566

EEF1A2 (untagged)-Human eukaryotic translation elongation factor 1 alpha 2 (EEF1A2)

SC118902 10 µg Ask for price

Rat EEF1A2 shRNA Plasmid

20-abx984646
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

EEF1A2 Antibody (C-term)

MBS9208327-008mL 0.08mL
EUR 210

EEF1A2 Antibody (C-term)

MBS9208327-04mL 0.4mL
EUR 430

EEF1A2 Antibody (C-term)

MBS9208327-5x04mL 5x0.4mL
EUR 1910

Mouse EEF1A2 shRNA Plasmid

20-abx970114
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human EEF1A2 shRNA Plasmid

20-abx951333
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human EEF1A2 Protein Lysate

MBS8410894-002mg 0.02mg
EUR 365

Human EEF1A2 Protein Lysate

MBS8410894-5x002mg 5x0.02mg
EUR 1410

EEF1A2 Peptide - middle region

MBS3233881-01mg 0.1mg
EUR 180

A number of different research investigating the advantages of ivermectin for malaria functions are ongoing/deliberate.Whereas ivermectin MDA provides promising views within the combat in opposition to malaria, we spotlight the added advantages and anticipated challenges of conducting future research in onchocerciasis-endemic areas, that are confronted with a considerable illness burden together with onchocerciasis-associated epilepsy.

Rising the frequency of ivermectin MDA in such locations could scale back the burden of each malaria and onchocerciasis, and permit for extra entomological investigations on each the Anopheles mosquitoes and the blackflies.

Upfront, acceptability and feasibility research are wanted to evaluate the endorsement by the native populations, in addition to the programmatic feasibility of implementing ivermectin MDA a number of occasions a yr.Onchocerciasis-endemic websites would doubly profit from ivermectin MDA interventions, as these will alleviate onchocerciasis-associated morbidity and mortality, whereas doubtlessly curbing malaria transmission. Involving onchocerciasis applications and different related stakeholders within the malaria/ivermectin analysis agenda would foster the implementation of pluri-annual MDA in goal communities.

Leave a Comment